Polyoxidonium - instructions for use, doses, side effects, contraindications

Description:Tablets from white with a yellowish tint to yellow with an orange tint, flat-cylindrical, with a facet, with a risk - on the one hand and the inscription "PO" - on the other. It is allowed to have hardly noticeable impregnations of more intense color.

Pharmacotherapeutic group:Immunomodulating agent

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

Polyoxidonium® tablet 12 mg has an immunomodulatory effect. The drug increases the body's resistance against bacterial, fungal and viral infections. The basis of the mechanism of immunomodulatory action of Polyoxidonium® is an increase in the ability of leukocytes to phagocytose microbes,stimulate the production of cytokines that activate immunity at initially low levels, and increase antibody production to infectious agents.

Polyoxidonium ® activates phagocytes of peripheral blood and tissue macrophages, which facilitates faster elimination of the pathogen from the body in the presence of a foci of infection. In addition, Polyoxidonium® activates lymphoid cells located in regional lymph nodes, namely B cells that produce secretory IgA.

With sublingual use, Polyoxidonium activates lymphoid cells located in the nasal cavity, Eustachian tubes, oropharynx, bronchus. In addition, Polyoxidonium® activates the bactericidal properties of saliva.

When administered orally, Polyoxidonium® also activates lymphoid cells located in the lymph nodes of the intestine.

The consequence of this is an increase in the resistance of the respiratory, gastrointestinal tract and ENT organs to infectious agents.

Along with the immunomodulating action, Polyoxidonium ® has a pronounced detoxification and antioxidant activity, it has the ability to excrete toxins, heavy metal salts,inhibits lipid peroxidation. These properties are determined by the structure and high molecular weight nature of Polyoxidonium®.

The use of Polyoxidonium® on the background of secondary immunodeficiency states allows to increase the efficiency and shorten the duration of treatment, significantly reduce the use of antibiotics, bronchodilators, glucocorticosteroids, and prolong the period of remission.

The drug is well tolerated, does not have mitogenic, polyclonal activity, antigenic properties, does not have allergic, mutagenic, embryotoxic, teratogenic and carcinogenic effects.

Pharmacokinetics:

Polyoxidonium® Tablets 12 mg after ingestion are rapidly absorbed from the digestive tract, bioavailability is approximately 50%. Maximum concentration in blood plasma is achieved 3 hours after ingestion. Pharmacokinetics Polyoxidonium® is linear (concentration in blood plasma is proportional to the dose taken).

Polyoxidonium® is a hydrophilic compound. The apparent volume of distribution is approximately 0.5 l / kg, which indicates that the drug is distributed mainly in the intercellular fluid.The half-absorption period is 35 minutes, the half-life is 18 hours. In the body it is hydrolyzed to oligomers, which are excreted mainly by the kidneys. There is no cumulative effect.

Indications:

Polyoxidonium® tablets 12 mg are used in adults and adolescents over 12 years for the treatment and prevention of infectious inflammatory diseases (viral, bacterial and fungal etiology) that are not amenable to standard therapy. Polyoxidonium ® is used both in the acute stage and in the stage of remission: in complex therapy:

acute and chronic recurrent infectious and inflammatory diseases of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle ear;

allergic diseases complicated by recurrent bacterial, fungal and viral infections (including pollinosis, bronchial asthma);

for rehabilitation often and for a long time (more than 4-5 times a year) of ill persons;

as monotherapy:

for the prevention of recurrent herpetic infection;

for seasonal prevention of exacerbations of chronic foci of infections of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle ear;

in immunocompromised individuals for the prevention of influenza and other acute respiratory infections in the pre-epidemic period;

for the correction of secondary immunodeficiencies due to aging or exposure to adverse factors.

Contraindications:

Individual hypersensitivity. Children under 12 years.

Carefully:

Use with caution in acute renal failure, as well as with lactose intolerance, lactase deficiency, glucosogalactose malabsorption.

Pregnancy and lactation:

Application in pregnancy and lactation is contraindicated (clinical experience is not available). Excretion Polyoxidonium® with breast milk has not been studied.

Dosing and Administration:

Polyoxidonium® tablets 12 mg are administered orally and sublingually for 20-30 minutes before meals daily 1, 2 or 3 times a day: adults - in doses of 12 mg or 24 mg, adolescents from 12 years - at a dose of 12 mg. The method and dosage regimen is determined by the doctor depending on the diagnosis, severity and severity of the process.

RECOMMENDED TREATMENT SCHEMES

Sublingually:

- In inflammatory processes of the oropharynx (bacterial, viral and fungal nature) - 1 tablet 2 times a day after 12 hours for 10-14 days.In severe forms of herpetic and fungal infection of the oral cavity - 1 tablet 3 times a day after 8 hours for 15 days.

- With chronic diseases of the paranasal sinuses and chronic otitis - 1 tablet 2 times a day after 12 hours for 5-10 days.

- In chronic tonsillitis - 1 tablet 3 times a day after 8 hours for 10-15 days.

- In chronic diseases of the upper respiratory tract - adults 2 tablets 2 times a day, adolescents 1 tablet 12 mg 2 times a day after 12 hours for 10-14 days.

- For the prevention of influenza and acute respiratory infections, immunocompromised individuals suffering from acute respiratory infections more than 4 times a year in the pre-epidemic period, adults 2 tablets, adolescents 1 tablet 2 times a day 12 hours after 10-15 days.

Orally

- For chronic diseases of the upper respiratory tract - adults 2 tablets 2 times a day after 12 hours, adolescents 1 tablet 2 times a day after 12 hours, for 10-14 days.

Side effects:

No adverse effect of Polyoxidonium® was reported.

Overdose:

Cases of an overdose of Polyoxidonium® are not known.

Interaction:

Drug interaction is not established.It is possible to use Polyoxidonium® with many drugs, including compatible with antibiotics, antiviral, antifungal and antihistamine drugs, bronchodilators, glucocorticosteroids, cytostatics, β-adrenomimetics.

Special instructions:

Do not exceed these doses and the duration of treatment.

Effect on the ability to drive transp. cf. and fur:

Does not affect the ability to drive cars and control mechanisms.

Form release / dosage:Tablets containing 12 mg of Polyoxidonium®.

Packaging:

Tablets containing 12 mg of Polyoxidonium®, 10 pieces each in a contoured cell package of polyvinylchloride film and aluminum foil in a cardboard bundle with instructions for use, 1 or 2 packs per pack.

Storage conditions:

In dry, dark place at a temperature of 4 to 25 ° C.

Keep away from children.

Shelf life:

2 years. Do not use the drug after the expiry date printed on the package.

Terms of leave from pharmacies:Without recipe

Registration number:P N002935 / 04

Date of registration:15.09.2009

The owner of the registration certificate:NPO PETROVAKS PHARM, LLC NPO PETROVAKS PHARM, LLC Russia

Manufacturer: & nbsp

NPO PETROVAKS PHARM, LLC Russia

Information update date: & nbsp20.08.2015

Illustrated instructions

Instructions

Polyoxidonium® (Polyoxidonium®)